Full-Time

Territory Account Manager

GSK

GSK

10,001+ employees

Develops medicines, vaccines, and consumer health

No salary listed

Durham, NC, USA

Remote

Travel within the territory is required and may include overnight travel; most time will be spent in market.

Bachelor's

Category
Sales & Account Management (1)
Required Skills
Sales
Customer Service
Data Analysis

Get referred to GSK

See people who can refer or advise you

Requirements
  • A BA/BS degree is required.
  • At least 5 years of pharmaceutical sales experience is required.
  • At least 3 years of specialty experience is required.
  • Ability to travel domestically as necessary, including potential overnight travel, with most time spent in market.
  • A valid driver's license is required.
Responsibilities
  • Identify, target, and win new business by influencing healthcare professionals to adopt a new approach to HIV treatment.
  • Engage healthcare professionals, nurses, staff, and administrators to understand clinical, organizational, and financial challenges and opportunities within target accounts.
  • Use data analytics, business acumen, and market expertise to identify high-priority prospects.
  • Prepare and execute business plans tailored to each customer's needs and designed to help healthcare professionals scale their treatment model to reach more patients.
  • Coordinate and partner with cross-functional team members, including Clinical Nurse Educators and Field Reimbursement Managers, to deliver an integrated product experience.
  • Maintain a portfolio-based selling mindset and close internal communication loops to provide customers with a cohesive, integrated experience.
  • Provide customer service by anticipating and addressing healthcare professional problems, needs, and requests.
  • Deliver and adapt execution plans to achieve performance goals using key performance indicators, scaling of successes, and business problem solving.
  • Develop and foster relationships with influential customers and thought leaders.
  • Act consistently with the company's culture, expectations, and values.
  • Embrace ambiguity in a launch environment and use setbacks as opportunities to learn and grow.
  • Escalate issues and risks when needed and speak up about concerns.
  • Understand and follow compliance and regulatory guidelines.
Desired Qualifications
  • A degree in Business, Marketing, or Life Sciences.
  • Experience influencing and collaborating cross-functionally in a matrixed environment.
  • Experience achieving sales success in complex market-access coverage situations.
  • Experience working with healthcare professionals to procure, manage, and administer cold-chain treatment products.
  • Knowledge of HIV treatment or prevention markets.
  • Bilingual ability in Spanish, preferred but not required.
  • Experience partnering cross-functionally within an integrated account-team model involving multiple field-based team members.
  • Strong planning and organization skills, analytical ability, business acumen, decision-making ability, and problem-solving skills.
  • Excellent written and oral communication skills.

GSK is a global healthcare company focused on three main areas: Pharmaceuticals, Vaccines, and Consumer Healthcare. It develops medicines, vaccines, and consumer health products to improve health outcomes worldwide. Its products address diseases in respiratory, HIV, oncology, and immuno-inflammatory areas; vaccines for influenza, shingles, and COVID-19; and over-the-counter wellness products. The company relies on substantial R&D and strategic partnerships to bring new products to market and to address health needs. Revenues come from sales of medicines, vaccines, and consumer health items, often complemented by patient support programs and collaborations with governments and biotech partners.

Company Size

10,001+

Company Stage

IPO

Headquarters

London, United Kingdom

Founded

1891

Get referred to GSK

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Singapore approved Blenrep combinations August 19, 2026, expanding relapsed multiple myeloma access.
  • GSK licensed AID351 August 17, 2026, adding a worldwide dengue program.
  • Cambridge prelet and £400 million R&D build signal long-term UK investment and hiring.

What critics are saying

  • GSK launched a three-year £1.9 billion restructuring July 28, 2026, signaling severe margin pressure.
  • GSK terminated Alector neuroscience collaboration July 8, 2026, after late-stage and mid-stage failures.
  • Patent cliffs and pipeline dependence threaten GSK if Blenrep and AID351 stall by 2029.

What makes GSK unique

  • GSK owns a rare integrated franchise across vaccines, specialty medicines, and consumer healthcare.
  • Cambridge Biomedical Campus center, announced August 18, 2026, anchors translational R&D in Cambridge.
  • AID351 license and Blenrep approvals show strength in antibody development and commercialization.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

401(k) Retirement Plan

Remote Work Options

Flexible Work Hours

Paid Vacation

Paid Holidays

Hybrid Work Options

Wellness Program

Mental Health Support

Phone/Internet Stipend

Company News

Child Bereavement UK
Aug 20th, 2026
Philanthropy and major gifts.

Philanthropy and major gifts. Philanthropic giving and major gifts are crucial to the future of Child Bereavement UK, helping Child Bereavement UK to sustain its established services and build solid foundations for the charity to further evolve and innovate. Child Bereavement UK is extremely grateful to all its current donors who have joined Child Bereavement UK in ensuring that all families are able to access the support they need to rebuild their lives, when a child grieves or when a child dies. How can I give a gift? At Child Bereavement UK, Child Bereavement UK is very grateful for gifts of any size. Major gifts can be given to support its core work of supporting families and educating professionals, or as a restricted donation pertaining to a specific project or area of its work. Child Bereavement UK is able to give you guidance on gift aid and tax efficient giving and can accept most forms of charitable giving including through Trusts and Foundations, CAF, BACS, cheque and international donations via IBAN, Swift, CAF America and CAF American Donor Fund. The Patron's Pledge. For annual gifts, Child Bereavement UK has The Patron's Pledge which is supported by its Royal Patron HRH The Prince of Wales. The Patron's Pledge brings together philanthropic individuals and organisations who pledge their long-term support on an annual basis. This support is vital in enabling Child Bereavement UK to plan future growth with more certainty and increase its reach to communities where support is most needed. Child Bereavement UK will arrange an individual plan with you around when and how you would like to make your donations; these can be made annually, quarterly or via monthly direct debits. Child Bereavement UK had been keen supporters of Child Bereavement UK for several years when Child Bereavement UK made the decision to deepen its commitment by joining the Patron's Pledge. Child Bereavement UK liked the idea of giving a dedicated donation over a number of years, enabling the charity to plan better for the future. Over the years Child Bereavement UK has developed strong personal connections with the charity and regularly speak about how they're finding new ways to meet the challenges of its changing times. Current member of The Patron's Pledge who has committed 10 years of support The Pearl Pledge. The Pearl Pledge, founded to mark its 30th year, is for individuals and companies who want to make a multi-year commitment to Child Bereavement UK that will have a lasting impact for thousands of bereaved families across the UK. GSK is proud to be the Founder Corporate Patron for the Pearl Pledge as part of its ongoing support for Child Bereavement UK. Child Bereavement UK know the support Child Bereavement UK give has a huge impact on children and families who are bereaved and look forward to seeing the progress of the Pearl Pledge initiative. Its promise to you. Child Bereavement UK recognise that providing support at this level requires deep trust and belief in its work and a desire to make a real difference to people's lives when they are faced with the devastation of child bereavement. Child Bereavement UK promise to work in partnership with you as a valued supporter and you will enjoy a close connection with the charity through a dedicated contact who will keep you informed of charity developments and important events, and who will regularly share the positive difference Child Bereavement UK is making together to the lives of those Child Bereavement UK support. Child Bereavement UK will endeavour to offer interesting suggestions for ways to be involved with its work and engage with its beneficiaries and will work with you to help you to achieve any goals you may have through your support of Child Bereavement UK. How your support could make a difference £1,000 could provide free places for up to 40 teachers on a bereavement awareness webinar, helping them to gain understanding of grief and loss for children and young people as well as providing practical support and resources. £3,600 could enable Child Bereavement UK to respond to 100 calls to its freephone Helpline from bereaved families or the professionals who are supporting them, providing a listening ear, guidance, and support. £8,401 could enable Child Bereavement UK to run its bereavement services around the UK for a day, helping children, young people, and families to rebuild their lives after the devastation of bereavement. £19,500 could provide a year of bereavement support for 25 families, helping families to rebuild their lives when a child grieves or when a child dies. £36,000 could enable Child Bereavement UK to respond to 1,000 calls to its freephone Helpline from families seeking a lifeline after the death of someone important to them. £59,210 could support its work with schools for six months, equipping school staff and teachers with the tools and confidence to support their school community after the death of a pupil, parent, or teacher. At Child Bereavement UK, Child Bereavement UK help to rebuild lives - but Child Bereavement UK rely on generous people like you to provide the firm foundations, thank you so much for your incredible support. Get in touch. If you'd like to know more about giving a major gift, The Patron's Pledge or Pearl Pledge, please contact its fundraising team: Email: [email protected] Telephone: 01242 515 157

PR Newswire
Aug 19th, 2026
GSK's Blenrep combinations approved in Singapore for relapsed/refractory multiple myeloma

Singapore's Health Sciences Authority has approved GSK's Blenrep (belantamab mafodotin) combinations for treating adults with relapsed or refractory multiple myeloma. The drug can be used with bortezomib plus dexamethasone in patients who have received at least one prior therapy, and with pomalidomide plus dexamethasone in patients who have received at least one prior therapy including lenalidomide. The approval is based on results from the DREAMM-7 and DREAMM-8 phase III trials. In DREAMM-7, the Blenrep combination nearly tripled median progression-free survival versus a daratumumab-based comparator. The trial also showed a 42% reduction in risk of death. Approximately 100 to 120 people are diagnosed with multiple myeloma annually in Singapore. Blenrep is the only anti-BCMA antibody-drug conjugate approved for multiple myeloma.

Linksbridge
Aug 19th, 2026
GSK nabs rights to anti-dengue antibody.

GSK nabs rights to anti-dengue antibody. August 19, 2026 Chugai Pharmaceutical and GSK are deepening their partnership on an anti-dengue antibody (AID351) targeting all four dengue virus serotypes. Tokyo-based Chugai announced Tuesday that it will exclusively license the candidate to GSK, which will steer it through clinical development and manufacturing. The agreement builds on a 2025 collaboration to jointly develop AID351. Chugai brought the drug through preclinical development with support from Japan's Global Health Innovative Technology Fund.

DrugDu
Aug 18th, 2026
BMS's new anti-tumor drug has been approved for marketing; GSK and Acyclovir are advancing clinical trials of their new drugs.

BMS's new anti-tumor drug has been approved for marketing; GSK and Acyclovir are advancing clinical trials of their new drugs. August 18, 2026 Source: drugdu 24 On August 13 local time, Bristol Myers Squibb (BMS) announced that the U.S. FDA has approved its innovative drug Iberdomide (Zenbexus) for marketing in combination with the standard treatment regimen (daratumumab + dexamethasone) for the treatment of relapsed or refractory multiple myeloma (MM) . According to the press release, Iberdomide is the first FDA -approved cereblon E3 ubiquitin ligase modulator (CELMoD) therapy. Iberdomide is the first product in BMS' CELMoD pipeline. Previously, the drug received Breakthrough Therapy Designation and Priority Review designation from the FDA for the treatment of relapsed or refractory multiple myeloma. This approval is based on the results of the Phase III EXCALIBER-RRMM (NCT04975997) study. This was a Phase III, multicenter, two-stage, randomized, open-label study designed to evaluate the efficacy and safety of the Iberdomide plus daratumumab and dexamethasone (ZDd) regimen versus the daratumumab, bortezomib, and dexamethasone (DVd) regimen in patients with relapsed or refractory multiple myeloma ( MM) . In China, the marketing application for Iberdomide was accepted by the CDE in December 2025 and included in the priority review process. The indication is for the treatment of adult patients with multiple myeloma who have received at least one line of prior therapy, in combination with daratumumab and dexamethasone. Approval is expected in Q4 of this year . On August 14, the official website of the Drug Clinical Trial Registration and Information Disclosure Platform showed that GlaxoSmithKline (GSK) registered a phase III, randomized, double-blind, placebo-controlled, three-arm study (ZENITH-2) evaluating the safety and tolerability of Efimosfermin alfa in participants with confirmed or suspected F2 or F3 stage metabolic-associated steatohepatitis (MASH) . Efimosfermin alfa, developed by Boston Scientific, is a potential best-in-class long-acting analogue of FGF21 (fibroblast growth factor 21), administered once monthly via subcutaneous injection. The product is designed to modulate key metabolic pathways to reduce liver fat, improve liver inflammation, and reverse liver fibrosis in MASH patients. In May of this year, GSK acquired the global development and commercialization rights to the product in a deal worth up to $ 2 billion, with an upfront payment of $ 1.2 billion. Aikebaifa's Class 1 new anti-influenza drug approved for clinical trials On August 13, Aike Baifa announced that its independently developed Class 1 new drug, AK0406 injection, has been approved by the China National Medical Products Administration (NMPA) to conduct clinical trials for influenza prevention. According to the press release, this is the company's first long-acting anti-influenza drug - an Fc conjugate (AFC). AK0406 is an innovative long-acting antiviral drug independently developed by AikeBaifa. By precisely conjugating a highly active antiviral small molecule with an antibody Fc fragment, it achieves long-term prevention and potential therapeutic applications before or after influenza exposure, meeting clinical prevention needs during peak influenza seasons. Preclinical studies show that the drug possesses broad-spectrum, highly active, and long-acting antiviral properties, with comprehensive optimization in structural design, antiviral activity, pharmacokinetics, and production. In terms of international clinical development, AK0406 was approved by the Australian Human Research Ethics Committee (HREC) in February this year to conduct a Phase 1 clinical trial. Currently, the enrollment and dosing of all healthy adult subjects in Australia have been successfully completed, and the trial has entered the follow-up phase. https://mp.weixin.qq.com/s?__biz=MjM5MTcyMjYxMw==&mid=2651881222&idx=2&sn=8b91c350b421da6ccd3a63f1b746cb46&chksm=ts4ricb1ttqgmyaai571q2he8dsg66uenq9g800q4go11l8hrkst3ney20hgh3glkuhnoekxz3ro

The Pharma Letter
Aug 18th, 2026
Chugai grants GSK exclusive license for anti-dengue virus antibody AID351.

Chugai grants GSK exclusive license for anti-dengue virus antibody AID351. 18 August 2026 Japanese drugmaker Chugai Pharmaceuticals (TYO: 4519), which is majority owned by Swiss pharma giant Roche (ROG: SIX), announced that it has signed an exclusive license agreement with the UK's GSK (LSE: GSK) for the anti-dengue virus antibody AID351. The parties initially collaborated on AID351 last year, with GSK agreeing to perform activities and evaluate potential funding for the initiation of clinical studies. No financial terms of the deal have been disclosed. This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here. Try before you buy Free. 7 day trial access * All the news that moves the needle in pharma and biotech * Exclusive features, podcasts, interviews, data analyses and commentary from its global network of life sciences reporters. * Receive The Pharma Letter daily news bulletin, free forever. Become a subscriber £820. Or £77 per month * Unfettered access to industry-leading news, commentary and analysis in pharma and biotech. * Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results. * Daily roundup of key events in pharma and biotech. * Monthly in-depth briefings on Boardroom appointments and M&A news. * Choose from a cost-effective annual package or a flexible monthly subscription The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It's part of the key information for keeping me informed Chairman, Sanofi Aventis UK More on this story... 13 July 2026 1 April 2019 19 June 2026 Company news directory. Companies featured in this story. Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news Today's issue. 18 August 2026 Company spotlight. A Danish clinical-stage TechBio company using its proprietary AI-Immunology platform to design therapeutic vaccines for cancer and infectious disease, with a pipeline spanning personalized, off-the-shelf, and bacterial vaccine candidates. More features in biotechnology. 18 August 2026